Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

Last Updated: Tuesday, March 11, 2025

A retrospective observational study evaluated real-world treatment patterns and outcomes among 317 patients with metastatic HR+ HER2- breast cancer who were treated with first-line palbociclib plus fulvestrant. The researchers concluded that the data suggest favorable real-world outcomes among patients treated with this combination.

Future Oncology

Radiographics

Breast cancer surveillance in patients with a personal history of breast cancer: Updates and controversies

Frontiers in Oncology

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review

Journal of Clinical Oncology

Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Seminars in Nuclear Medicine

AI in breast cancer imaging: An update and future trends

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

HR+ HER2- Breast Cancer Resource Center